Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cyfuse Biomedical KKFSE:4892 +0.18%52 Debt-to-Equity is 0.47 as of Jun. 2026, which is 42% above its 10-year median of 0.33. GuruFocus rates FSE:4892 with a GF Score™ of 52/100 and a GF Value™ of 円2,202.02 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 811 Drug Manufacturers companies, Cyfuse Biomedical KK ranks worse than 67.57% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Cyfuse Biomedical KK's Debt-to-Equity or its related term are showing as below:
FSE:4892'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.24 Med: 0.33 Max: 0.48
Current: 0.47
During the past 6 years, the highest Debt-to-Equity Ratio of Cyfuse Biomedical KK was 0.48. The lowest was 0.24. And the median was 0.33.
FSE:4892's Debt-to-Equity is ranked worse than 67.57% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs FSE:4892: 0.47
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Cyfuse Biomedical KK Debt-to-Equity Related Terms
Cyfuse Biomedical KK Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Cyfuse Biomedical KK's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyfuse Biomedical KK Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Cyfuse Biomedical KK's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyfuse Biomedical KK (FSE:4892) has a Debt-to-Equity of 0.47 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cyfuse Biomedical KK and its competitors. This is 42% above median its historical median of 0.33. Over the past decade, Cyfuse Biomedical KK's Debt-to-Equity has ranged from 0.24 to 0.48. According to the industry distribution chart, Cyfuse Biomedical KK ranks #548 out of 811 companies in the Drug Manufacturers industry, placing it in the top 67.6%.
Is Cyfuse Biomedical KK's Debt-to-Equity too high?
Cyfuse Biomedical KK's current Debt-to-Equity of 0.47 is 42% above median its 10-year median of 0.33. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 0.48. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Cyfuse Biomedical KK's value of 0.47 is 67.9% above this industry median. Based on the distribution chart, Cyfuse Biomedical KK ranks #548 out of 811 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cyfuse Biomedical KK has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cyfuse Biomedical KK ranks #548 out of 811 companies for Debt-to-Equity. This places Cyfuse Biomedical KK in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Cyfuse Biomedical KK's value of 0.47 is 67.9% above this benchmark. Historically, Cyfuse Biomedical KK's own Debt-to-Equity has ranged from 0.24 to 0.48 over the past decade. While the company's 10-year median is 0.33 vs. the industry median of 0.28, Cyfuse Biomedical KK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cyfuse Biomedical KK's current Debt-to-Equity of 0.47 is 67.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cyfuse Biomedical KK and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyfuse Biomedical KK's current Debt-to-Equity is 0.47, which is 42% above median its own 10-year median of 0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (FSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円2,202.02, compared to a current price of 円561.00 — trading 74.5% below its estimated fair value. The current Debt-to-Equity is 0.47, which is 42% above median its 10-year median of 0.33 and 67.9% above the Drug Manufacturers industry median of 0.28. Cyfuse Biomedical KK's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cyfuse Biomedical KK (FSE:4892), the current Debt-to-Equity is 0.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyfuse Biomedical KK (FSE:4892) Overvalued in 2026?
Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued.
The current stock price of 円561.00 is trading 74.5% below its estimated GF Value™ of 円2,202.02.
GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.
Key valuation signals for FSE:4892:
Debt-to-Equity: 0.47 (42% above median its 10-year median of 0.33)
GF Value™: 円2,202.02 vs. price of 円561.00 (74.5% below fair value)
Industry Position: 67.9% above the Drug Manufacturers median (#548 of 811)
No single metric tells the full story. See the FSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
52GF Score
Get the complete analysis for FSE:4892
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4892 has been successfully added to your 
